Full Text View
Tabular View
No Study Results Posted
Related Studies
The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration
This study is currently recruiting participants.
Study NCT00589134   Information provided by Yale University
First Received: January 2, 2008   Last Updated: February 13, 2009   History of Changes

January 2, 2008
February 13, 2009
January 2006
December 2009   (final data collection date for primary outcome measure)
osmotic regulation of AVP [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00589134 on ClinicalTrials.gov Archive Site
temperature responses [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
 
The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration
The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration

Women are at greater risk for exercise-induced hyponatremia (low blood sodium concentration) and this risk has been attributed to their lower body weight and size, excess water ingestion and longer racing times relative to men. While these factors contribute to the greater incidence of hyponatremia in women, it is likely that their greater levels of estradiol in plasma and/or tissue also play a role in increasing the risk of hyponatremia in women. More importantly, estradiol may also leave women more susceptible to the extreme consequences of hyponatremia (i.e. brain damage, death). Hyponatremia is generally attributed to inappropriately elevated levels of the hormone arginine vasopressin (AVP). AVP is the most important hormone controlling water retention in the kidney. Earlier studies in our laboratory have demonstrated that estradiol lowers the threshold for thirst sensation and AVP release during exercise. The purpose of these studies is to test the hypotheses that in women with a history of hyponatremia, estradiol lowers the thresholds for thirst and AVP release, leading to greater fluid retention, lower blood sodium concentration during endurance exercise in the heat. However, we further hypothesize that progesterone administration along with estradiol administration will attenuate the effect of estradiol on the regulation of thirst and AVP, normalize fluid retention, and serum sodium concentration during endurance exercise in the heat. In women without a history of hyponatremia, we expect that estradiol administration will lower the thresholds for thirst and AVP release, but will not increase fluid retention or reduce blood sodium concentration during endurance exercise in the heat. We hypothesize that progesterone administration along with estradiol administration will attenuate the effect of estradiol on thirst and AVP, but have no effect on fluid retention or serum sodium concentration during endurance exercise in the heat. To test these hypotheses, women will perform endurance exercise in the heat under three hormonal conditions: 1) during Gonadotropin-releasing hormone (GnRH) antagonist alone--which will suppress estradiol and progesterone; 2) during GnRH antagonist+estradiol; and 3) during GnRH antagonist+estradiol+ progesterone. During exercise, fluid will be replaced with either water or a carbohydrate-electrolyte beverage (random assignment).

 
 
Interventional
Basic Science, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Exercise Induced Hyponatremia
  • Dietary Supplement: Gatorade Endurance Formula
  • Other: ganirelix acetate
Experimental: type of beverage
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
26
December 2009
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy volunteers (18-35 yrs) with and without previous exercise induced hyponatremia

Exclusion Criteria:

  • conditions that would preclude safe exercise or safe use of hormones
Female
18 Years to 35 Years
Yes
Contact: Nina Stachenfeld, PhD 203-562-9901 ext 219 nstach@jbpierce.porg
Contact: Cheryl Leone, MA 203-562-9901 ext 266 cleone@jbpierce.org
United States
 
NCT00589134
Craig Horswill, Gatorade Sports Science Institute
188, 0508000538
Yale University
 
Principal Investigator: Nina Stachenfeld, PhD John B. Pierce Laboratory
Yale University
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP